Since the begining of social media time, this has been my nic, and the real name and age, Garfield Goose, King of the United States from Chicago's WGN Frazier Thomas rip. Let snowden be a reminder to you, and God Bless America.
Nov 8 (Reuters) - U.S. regulatory officials have raised concerns about "multiple serious and potentially fatal safety issues" in patients given Sanofi's new multiple sclerosis drug Lemtrada, fuelling uncertainty about whether it will be approved.
Food and Drug Administration (FDA) staff said in a report prepared ahead of a Nov. 13 advisory panel that the risks might be too great to justify approval in the world's biggest pharmaceutical market, unless the drug showed "substantial clinical benefit."
Lemtrada, an injectable treatment also known as alemtuzumab, is one of two new Sanofi drugs for MS, an autoimmune disease that attacks the central nervous system and affects more than 2 million people worldwide.
The FDA is expected to rule on the drug by the end of the year. Lemtrada won marketing authorisation from the European Commission in September, shortly after obtaining approval for its MS pill Aubagio.
The current consensus for annual Lemtrada sales worldwide is $752 million by 2018, according to forecasts compiled by Thomson Reuters Pharma.
Shares in Sanofi fell as much as 2.5 percent after the documents were posted on the FDA's website on Friday. By 1555 GMT, they had narrowed their loss and were down 0.8 percent at 78.01 euros.
"Briefing documents usually raise many questions that are open for discussion at the upcoming meeting. But when we read the document it is clearly more negative than usual," a Paris-based trader said.
IMMUNE SYSTEM RISK
Multiple sclerosis is a chronic, often disabling disease that attacks the central nervous system and can lead to numbness, paralysis and loss of vision.
Lemtrada is given via an intravenous drip for five days and for three days one year later. It is designed to re-programme the immune system, but in doing so can make the body more vulnerable to other diseases.
The FDA staff review cited risks of autoimmune diseases including blood disorders, infections and cancer, and, noting that these issues were "serious and
POOR management just does NOT ring TRUE:
Dr. Milind S. Deshpande Ph.D., 56
Chief Exec. Officer, Pres and Director
Ms. Mary Kay Fenton , 49
Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec.
Dr. Gautam Shah Ph.D., 56
Chief Compliance Officer and Exec. VP
Mr. Joseph Truitt , 48
Chief Commercial Officer and Sr. VP of Bus. Devel.
Shazam Stocks, and you are correct. This company is obviously no stranger to reverse splits, so why not issue a gabillion shares? There is not enough $$ to take it to the next level. So, buying 3 shares is like buying 1,000 shares pre reverse splits. What say you Shazam? Yes, I own 166,666 shares (pre split).
Did I mention this October 18, 2013 1:36 when the price was at $4.30? Thumbs down if you were too stupid to listen please.
Uh, I can't remember what this nic means, but I think it was for a company that acts like the NSA and prohibits freedom of speech, and at the time was run by a bunch of no good $%#@!*%! asians.
These vaginal bashers are all posting from nicaraguan internet cafes, check out their IP adresses. It is the same kids that send "I was mugged in Spain and all my cash and passport stolen. Please send $$ to account xxx". Look at the poor grammar and repetitive nature of the posts. As an ex NSA profiler, I can assure you these people are being investigated. In the words of Gen. Keith Alexander, these guys are a bunch of phoney balonies.
REITs are required to distribute at least 90% of their taxable income into the hands of investors.
Look at the quarterly earnings. Do the math and watch the boiler room paid morons go vaginalistic on this!
The exchanges are kicking in October 1st:
The Medicare Part D prescription drug doughnut hole continues to close, with even greater discounts. The discount in 2014 is 52.5 percent for brand-name drugs and 28 percent for generic drugs. Copied from AARP
Each year the discount % is greater.